Abstract
Killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, γ-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering apoptosis, the cells intrinsic death program. Accordingly, defects in apoptosis pathways can result in cancer resistance to current treatment approaches. Understanding the molecular mechanisms that regulate cell death programs including apoptosis, and how resistant forms of cancer evade apoptotic events, may provide novel opportunities for cancer drug development.
Keywords: apoptosis, cancer, mitochondria, cancer therapy, resistance
Current Cancer Drug Targets
Title: Targeting Apoptosis Pathways in Cancer Therapy
Volume: 4 Issue: 7
Author(s): Simone Fulda and Klaus-Michael Debatin
Affiliation:
Keywords: apoptosis, cancer, mitochondria, cancer therapy, resistance
Abstract: Killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, γ-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering apoptosis, the cells intrinsic death program. Accordingly, defects in apoptosis pathways can result in cancer resistance to current treatment approaches. Understanding the molecular mechanisms that regulate cell death programs including apoptosis, and how resistant forms of cancer evade apoptotic events, may provide novel opportunities for cancer drug development.
Export Options
About this article
Cite this article as:
Fulda Simone and Debatin Klaus-Michael, Targeting Apoptosis Pathways in Cancer Therapy, Current Cancer Drug Targets 2004; 4 (7) . https://dx.doi.org/10.2174/1568009043332763
DOI https://dx.doi.org/10.2174/1568009043332763 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Pathological Brain Image Segmentation and Classification: A Survey
Current Medical Imaging Editorial [Hot topic: Current Formulations and Techniques of Drug/gene Delivery for Targeted Therapy and Tissue Engineering (Executive Editors: Chi-Hwa Wang and Sudhir H. Ranganath)]
Current Pharmaceutical Design Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Alpha-Interferon and Its Effects on Signalling Pathways Within Cells
Current Protein & Peptide Science Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Application of Spray-drying and Electrospraying/Electospinning for Poorly Watersoluble Drugs: A Particle Engineering Approach
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomarkers Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Meet Our Editorial Board Member
Current Neuropharmacology MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Current Targets for Anticancer Drug Discovery
Current Drug Targets Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design Histone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Current Enzyme Inhibition Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy